Sociedad Americana de Hirudoterapia

Utilization of Leech Therapy after Rhinoplasty

Research article published in Plastic and reconstructive surgery (2022)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosShtraks J, Peng G, Nassif P · Plastic and reconstructive surgery, 2022

Abstract

BACKGROUND: The use of medicinal leeches in modern reconstructive surgery is well-described. Leech therapy after rhinoplasty has not been previously well-characterized. METHODS: The medical records of all patients who underwent open rhinoplasty by a single surgeon over a 4-year period were reviewed. Patient demographics, including age, sex, medical comorbidities, number of previous rhinoplasty surgeries, time to utilization of leech therapy, adjunct therapies used, resolution of skin changes, and smoking status, were recorded. Operative reports were reviewed for pertinent information, including number of tip grafts used, graft materials used, and placement of septal extension grafts or "unicorn" grafts. RESULTS: Between April of 2016 and March of 2020, 545 patients underwent rhinoplasty performed by the senior author (P.S.N.). Of these patients, 39 (7.2 percent) underwent leech therapy postoperatively. The mean age of included patients was 47.4 years. Of the patients who required leech therapy, 34 (87.2 percent) had undergone revision rhinoplasty. The mean number of previous rhinoplasties was 3.4. The mean number of tip grafts used was 2.6. Thirty-three patients (84.6 percent) had either a traditional septal extension graft or unicorn graft placed. Nine patients (23.1 percent) were former smokers. Complete resolution of skin color changes was seen in 38 patients (97.4 percent). There were no major complications after leech therapy. CONCLUSIONS: Leech therapy is a useful tool for the rhinoplasty surgeon, particularly in the setting of complex revision rhinoplasty, in patients who have undergone multiple previous nasal surgical procedures, or in patients who require significant cartilage grafting to reconstruct the nasal tip or lengthen the nose. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsCartilageHumansLeechingMiddle AgedNasal SeptumNoseRetrospective StudiesRhinoplastyTreatment Outcome

Resumen

The use of medicinal leeches in modern reconstructive surgery is well-described. Leech therapy after rhinoplasty has not been previously well-characterized.

Por qué esto importa para la hirudoterapia

Este estudio reporta la experiencia de un solo cirujano con terapia con sanguijuelas postoperatoria tras rinoplastia abierta, en la cual 39 de 545 pacientes (7.2%) recibieron tratamiento con sanguijuela—predominantemente tras procedimientos de revisión (87.2%)—con resolución completa de los cambios adversos del color de la piel observada en el 97.4% y sin complicaciones mayores. Este trabajo es directamente relevante para la hirudoterapia, ya que proporciona datos de resultados clínicos sobre el uso de sanguijuelas medicinales en cirugía plástica facial y refuerza el papel establecido de la terapia con sanguijuelas en el manejo de la perfusión tisular comprometida en diversos contextos reconstructivos. Los hallazgos reflejan la práctica y la población de pacientes de un solo cirujano, no aportan datos sobre especies de sanguijuela, componentes del secretoma salival o mecanismos farmacológicos subyacentes a los efectos clínicos observados, y no establecen protocolos de tratamiento óptimos para una aplicación más amplia.

Citación

Utilization of Leech Therapy after Rhinoplasty.

Shtraks J, Peng G, Nassif P · Plastic and reconstructive surgery, 2022

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: March 18, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.